Furthermore, IA administration of gemcitabine resulted in increased evidence of both apoptosis (i.e. an increased expression of cleaved caspase 3) and necrosis in pancreatic tumor samples compared to animals which received same dose IV, thereby demonstrating that the effects of gemcitabine on the tumor are enhanced following targeted delivery. This evidence concerns the gene CASP3 and pancreatic neoplasm.